1	Retrospective feasibility study of Mycobacterium tuberculosis modified
2	lipoprotein as a potential biomarker for TB detection in children
3	
4	Xinxin Yang, <sup>a,b</sup> Matthew F. Wipperman, <sup>a,c</sup> Sharon Nachman, <sup>d</sup> Nicole S. Sampson <sup>a,#</sup>
5	
6	<sup>a</sup> Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400
7	<sup>b</sup> Chronus Pharmaceuticals, Inc., 25 Health Sciences Drive, Stony Brook, NY 11790
8	<sup>c</sup> Current address: Clinical and Translational Science Center, Weill Cornell Medicine,
9	New York, NY 10065
10	<sup>d</sup> Department of Pediatrics, Renaissance School of Medicine, Stony Brook University,
11	Stony Brook, NY 11794-3400
12	
13	Running title: Retrospective Mtb lipoprotein biomarker in children
14	
15	<sup>#</sup> Corresponding author: nicole.sampson@stonybrook.edu
16	
17	Abstract
18	Background: Current TB diagnostic methods available have been developed for adults
19	and development efforts have neglected the differences in disease and sampling that
20	occur between adults and children. Diagnostic challenges are even greater in HIV co-
21	infected children and infants.
22	Methods and results: We established a sandwich ELISA assay to detect
23	Mycobacterium tuberculosis modified lipoprotein (TLP) ex vivo in plasma. The study

- 24 population contains plasma samples from 21 patients with active TB and 24 control
- 25 samples with no TB, collected in the International Maternal Pediatric Adolescent AIDS
- 26 Clinical Trails (IMPAACT) P1041 study. Retrospective analysis was performed and the
- 27 result demonstrate that TLP level is associated with TB disease.
- 28 **Conclusions:** Plasma levels of TLP associate with active TB disease in HIV positive
- 29 subjects and can be used as an indicator for TB detection in children.

30 Childhood TB is estimated to contribute 12% of the disease burden, with 31 approximately 10 million cases in 2019 worldwide (1). Existing gold-standard diagnostic 32 culture tools fail to confirm TB in most children, who typically have low bacterial counts 33 and cannot produce sputum like adults. Diagnostic challenges are great in HIV co-34 infected children and infants (2), where the clinical presentation of pulmonary TB may 35 be non-specific (3), acute (4, 5), and chest radiographs may be atypical (2). Although 36 rates of bacteriological confirmation appear similar in HIV-infected and uninfected 37 children (6), diagnostic delay and HIV-related immune pathology contribute to higher 38 rates of TB disease progression with increased disease severity, morbidity, and 39 mortality (7-10). Infants, young children, and HIV-infected children are at increased risk 40 of developing TB following infection and of disseminated or severe disease, including 41 TB meningitis (11). Because TB in children is typically paucibacillary, even if a sputum 42 sample or gastric aspirate is obtained, the utility of PCR based diagnostic methods like 43 GeneXpert is limited. More sensitive and child-friendly diagnostic tools are urgently 44 needed to diagnose TB in children (12).

45 Mycobacterium tuberculosis (Mtb) is an intracellular pathogen that is capable of 46 surviving and replicating within macrophages, the frontline of the innate host defense, 47 and has evolved multiple mechanisms to escape these immune cells (13). One of the 48 immune evasion strategies of *Mtb* is the deregulation of lipid metabolism, leading to the 49 formation of foamy macrophages (FM), a hallmark of granulomata in tuberculosis 50 lesions (14). However, only pathogenic mycobacterial strains including *M. tuberculosis* 51 (15), *M. avium*, *M. abscessus*, or *M. bovis*, but not non-pathogenic mycobacterial 52 strains, like *M. smegmatis*, induce foam cell formation upon infection (16, 17). Foam

53 cells are associated with chronic inflammation in many metabolic diseases and certain 54 cancers besides infectious diseases (18, 19). For example, foamy macrophages are critical to the initial formation, development, and instability of atherosclerotic plagues 55 56 and are therefore therapeutic targets in atherosclerosis. Foam cell formation is induced 57 primarily by malondialdehyde-modified low density lipoprotein (MDA-LDL) and not by 58 native or extensively oxidized LDL in atherosclerosis (20). Elevated plasma levels of 59 MDA-LDL in patients are associated with acute coronary syndromes and are used as diagnostic tools clinically (21). 60

In this study we identified human lipoprotein modification specific to exposure to *Mtb.* The pathogen modified host lipoprotein, TLP, is detectable ex vivo in plasma using a sandwich ELISA assay. We further evaluated the association between the presence of TLP and TB disease status in children.

65

# 66 MATERIALS AND METHODS

67 Preparation of malondialdehyde-conjugated LDL (MDA-LDL) (20) and Mtb-68 *modified lipoprotein (TLP).* HepG2 human liver cells (ATCC HB-8065) were grown to 69 80% confluence in HepG2 growth media (DMEM, 10% fetal bovine serum, 20 mM L-70 glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, and 10 mM HEPES). Cells 71 were grown for 4-5 days and culture supernatants were then harvested and 72 concentrated. LDL particles were separated by density gradient ultracentrifugation and 73 desalted by ultrafiltration through a 100-kDa molecular weight filter. MDA-LDL was prepared by incubation 2 mg protein/mL of LDL with 2 µM acrolein at 37 °C for 24 h 74 75 under nitrogen atmosphere. Mycobacterium tuberculosis was cultured in Middlebrook

76 7H9 (broth) supplemented with 0.2% glycerol, 0.5% BSA, 0.08% NaCl, 0.05% (v/v)

tyloxapol to OD~0.7. LDL was added and the culture was incubated at 37 °C for 7 days.

TLP was isolated from the culture supernatant, concentrated and washed with PBS.

79 Agarose gel electrophoresis and western blot analysis. Agarose gel 80 electrophoresis was performed in 0.06 M barbital buffer (pH 8.6). The gel was 0.8% and 81 stained with Sudan Red 7B. Lipoproteins were separated on a 6% sodium dodecyl 82 sulfate polyacrylamide gel electrophoresis (SDS-PAGE), proteins were transferred to a PVDF membrane and immunoblotted with specific antibodies. The primary antibodies 83 84 used for western blot were monoclonal anti-LDL (MDA oxidized) antibody (Abcam) and 85 polyclonal anti-apoB Ab (H-300, Santa Cruz). Membranes were treated with anti-mouse, or anti-rabbit IgG HRP conjugates as secondary antibodies. 86

87 **THP-1** macrophage preparation and treatment. THP-1 cells (ATCC TIB-202) 88 were maintained in RPMI-1640 medium containing heat-inactivated 10% fetal bovine 89 serum (FBS), 0.05 mM 2-mercaptoethanol, 100 U/mL penicillin and 100 mg/mL 90 streptomycin (RPMI complete medium). The cells were plated into 6-well plates containing coverslips  $(1.5 \times 10^6 \text{/well})$ , treated with phorbol 12-myristate 13-acetate 91 92 (PMA, 150 nM) in RPMI complete media. Media was replaced with fresh RPMI 93 complete media at 48 hours after plating. At 72 hours after media change, THP-1 94 macrophages were treated with LDL, MDA-LDL and TLP at 200 µg/mL in PBS for 24 95 hours. All cells were incubated in a humid atmosphere at 37°C with 95% air and 5% 96 CO<sub>2</sub>.

*Lipid body staining and immunostaining.* Following lipoprotein treatment,
 macrophages were washed with PBS and fixed with 4% paraformaldehyde at room

temperature for 30 minutes. Cells were stained with Oil Red O solution for 20 minutes at
room temperature. The slides were then counterstained with haematoxylin and
observed under an inverted microscope (Zeiss Axiovert 200M). Percent foam cell
formation was quantified by counting stained versus total cells in 10 fields.

103 Generation of anti-TLP antibodies (22, 23). Monoclonal antibodies against 104 TLP were identified utilizing Human Combinatorial Antibody Library (HuCAL, Bio-Rad 105 AbD Serotec GmbH). The HuCAL phage display library was depleted of antibodies that 106 recognize intact LDL. The depleted library was panned for three rounds of binding, 107 elution, and amplification to isolate antibodies specific for TLP. Binding of anti-TLP 108 antibodies to control antigens including BSA, HSA, N1-CD33-His6 and intact LDL, was 109 checked by indirect ELISA assays, with anti-TLP antibodies as primary antibodies and 110 an anti-Fab-AP conjugate (Bio-Rad) as a secondary antibody.

111 Sandwich ELISA assay. Briefly, 96 well plates were coated overnight at 4°C 112 with 5 µg/mL capture antibody (AbD28580, amino acid sequence shown in Table S2) in 113 phosphate buffered saline (PBS). Plates were washed with PBS containing 0.05% Tween-20 (PBST) 3 times, blocked with 3% BSA in PBST for 1 hour at room 114 115 temperature. Then serial dilutions of standards and test samples in HISPEC assay 116 diluent (Bio-Rad) were loaded and allowed to react for 2 hours at room temperature. 117 Plates were then washed 3 times with PBST and treated with 2 µg/mL of HRP 118 conjugated detection antibody (AbD28582) in HISPEC assay diluent for 1 hour at room 119 temperature. After washing 6 times with PBST, the plates were developed with 120 QuantaBlu fluorogenic peroxidase substrate kit (Thermo Scientific) for 30 min at room 121 temperature. Fluorescence was recorded (ex.  $320 \pm 25$ nm, em.  $430 \pm 35$ nm).

122 Subjects and samples. Retrospective analysis was performed on a total of 45 123 plasma samples from International Maternal Pediatric Adolescent AIDS Clinical Trails 124 (IMPAACT) P1041 (24, 25). P1041 was a Phase II/ III, randomized, double-blind, 125 placebo-controlled clinical trial to evaluate the efficacy of isoniazid prophylaxis on TB 126 disease and latent *Mtb* infection free survival in HIV-infected and HIV-exposed, but 127 uninfected infants up to 192 weeks of follow up (25, 26). Samples include 24 with noTB 128 and 21 with TBDIS, all HIV infected. Patients without *Mtb* infection were categorized as 129 noTB; patients with a positive tuberculin skin test but lacking any clinical, radiographic 130 or laboratory evidence of disease caused by Mtb were categorized as latent TB 131 infection (LTBI); and patients presenting clinical, radiographic or laboratory evidence of 132 disease caused by *Mtb* were categorized as TBDIS. Plasma samples were collected, 133 frozen and thawed before use.

Statistical Analysis. Categorical variables were compared using t-student test, whenever appropriate. Non-parametric tests (Mann-Whitney) were used for nonnormally distributed variables. Assay accuracy, including 95% confidence intervals, was assessed using sensitivity, specificity, predictive values and area under the ROC in the TB and non-TB groups. Statistical calculations were performed with GraphPad Prism® Software.

140

#### 141 **RESULTS**

Mtb modified lipoprotein (TLP) is different from MDA-LDL. We purified and
 treated native LDL with *Mycobacterium tuberculosis* in vitro to obtain *Mt*b modified
 lipoprotein (TLP). Decreased mobility of TLP in agarose electrophoresis indicates that

145 TLP is more positively charged than native LDL (Figure 1A). In contrast, MDA-LDL, one 146 of the end products of lipid peroxidation, is more negatively charged than native LDL 147 (20). The increased size of TLP compared to native LDL was also confirmed by 148 dynamic light scattering analysis (Table S1). Furthermore, TLP is recognized by anti-149 apolipoprotein B (apoB) antibodies but not anti-MDA-LDL antibodies, indicating TLP 150 does not contain a malondialdehyde-modified apoB derivative (Figure 1B). We 151 demonstrate that LDL is altered in the presence of *Mtb*, and the resulting TLP is distinct 152 from the typical atherosclerotic species malondialdehyde-modified LDL (MDA-LDL) 153 present in human blood (27).





В

- 155
- 156 A



- showing TLP is recognized by anti- apolipoprotein B (apoB) antibodies (top) but not
- 160 anti- MDA-LDL antibodies (bottom).
- 161

162 *Mtb modified LDL induces lipid body accumulation in macrophages.* The

163 induction of foamy macrophages have been reported as hallmarks in many pathologies

164 associated with chronic proinflammatory stimuli including atherosclerosis (15). It has 165 also been reported that Mtb lipids induce the formation of giant multinuclear 166 macrophages (28). We therefore used foamy macrophage formation as a tool to assess 167 the bioactive components that trigger a tissue response similar to granuloma formation 168 in TB. Lipid bodies were stained with Oil red O. The buffer control showed no 169 accumulation of lipid bodies and the cells remained rounded (Figure 2A). LDL treated 170 macrophage showed some lipid accumulation, with a commensurate increase in cell 171 size (Figure 2B). In contrast, MDA-LDL, commonly associated with atherosclerosis, 172 treated macrophages exhibited more extensive accumulation of lipid bodies than the 173 LDL treated macrophages. These macrophage phenotypes are consistent with previous 174 reports of in vitro foamy macrophage formation (20, 29). Most importantly, TLP treated 175 macrophages had extensive lipid body accumulation per cell compared to macrophages 176 treated with other LDLs (Figure 2 and S1B). Moreover, the TLP-treated macrophage 177 morphology was distinct from other samples. The majority of the TLP-treated 178 macrophages became multinucleated (Figure 2D and S1A) and developed long 179 filopodia consistent with cell migration or exocytosis. Thus, we hypothesize that the 180 modified LDL is detectable in vivo to serve as a biomarker for TB disease, and an 181 antibody specific for recognition of TLP is an *Mtb*-specific indicator of infection and 182 progression to (active) TB disease.

183



190

191 Anti-TLP monoclonal antibodies were generated and a TLP Sandwich 192 ELISA assay was established. We generated 13 anti-TLP monoclonal antibodies 193 (Fad-A-FH, bivalent Fab-bacterial alkaline phosphatase fusion antibody followed by FLAG<sup>®</sup> and His6-tag) from the Human Combinatorial Antibody Library (HuCAL, Bio-Rad 194 195 AbD Serotec GmbH) using in vitro selection and counter selection (22, 23). HuCAL is a 196 phage display library containing highly specific, fully human monoclonal antibodies, with 197 DNA sequence encoded for each antibody fragment. The HuCAL phage display library 198 was depleted of antibodies that recognize LDL (Figure S2). The depleted library was 199 panned for three rounds of binding, elution, and amplification to isolate antibodies 200 specific for TLP. Among the antibody hits selected, 13 antibodies were identified as 201 unique by DNA sequencing. These antibodies were produced heterologously for further 202 development. The cross-reactivity with native LDL, human serum albumin, bovine 203 serum albumin, and His<sub>6</sub> affinity tag was determined in an indirect ELISA format. Eight 204 antibodies showed a specific signal for TLP at least 4-fold above native LDL 205 background (Figure S2). We tested pairwise combinations of antibodies to identify

antibody pairs that have non-overlapping epitopes suitable for use in a sandwich ELISA (Figure S3A). 5 sandwich pairs were identified with good signal over background and the assay conditions were optimized for the best pair, AbD28582 and AbD28580 (amino acid sequence shown in Table S2). We established the linear response of the sandwich ELISA (Figure S3B) to antigen spiked into pediatric plasma. TLP is specifically detected at >=4ppm in the presence of plasma LDL, which is around  $10^6$  ng/mL (30).

212 Levels of TLP are increased in patients with active TB compared to no TB 213 controls. We assayed stored plasma samples from the HIV IMPAACT P1041 trial for 214 the presence of TLP. The median plasma levels of TLP was 494 ng/mL in control subjects, and 2.7 fold higher in active TB subjects (Figure 3A). The difference between 215 216 control subjects and active TB subjects is significant (p<0.001). The receiver operating 217 characteristic (ROC) analysis describes the relationship between the sensitivity and 218 specificity at any cut-off values. An ROC curve of TLP concentration for active TB 219 versus control subjects is presented in Figure 3B. The area under the ROC curve (AUC) 220 is 0.86 (95% CI=0.75-0.97, p<0.0001). An optimal cutoff of 1064 ng/mL rendered 71% 221 sensitivity and 88% specificity. Alternatively, a cutoff of 1230 ng/mL provided 57% 222 sensitivity and of 96% specificity.

223



### Figure 3. Retrospective analysis of P1041 HIV positive plasma samples. (A)

Plasma levels of TLP in HIV positive subjects clinically diagnosed probably having active stage tuberculosis disease (TB) and not having TB (noTB). Individual patients are depicted as dots with group mean. The dashed line represents the detection limit of the assay. \*\*\* p<0.001. (B) ROC curve of TLP concentration for active TB versus control subjects of HIV positive patients. AUC, area under curve. The dashed line represents the no-discrimination line from the left bottom to the top right corners.

233

234 We also monitored apoB levels, i.e., LDL levels, of all the samples using Human 235 apoB ELISA kits (ab190806, Abcam) and found there was no linear correlation between 236 TLP and apoB levels (Figure S5A), suggesting that plasma LDL fluctuation does not 237 interfere with TLP detection. There is a weak correlation between TLP levels and time 238 before or after diagnosis (Figure S5). The samples collected before diagnosis may 239 represent disease progression from no infection or infection but without clinical signs of 240 disease to outward manifestation of disease. Samples collected after diagnosis may 241 represent a mixed outcome of disease progression and anti- tubercular treatment. We

242 do not have additional sample sets to demonstrate if anti-tubercular treatment affects 243 TLP levels. However, the discrimination of TLP levels between control subjects and 244 active TB subjects (post diagnosis with treatment less than 40 weeks) was improved 245 with the exclusion of samples collected after 40 weeks of treatment (p<0.0001), which 246 may represent patients clear of TB. ROC (Receiver operating characteristic) analysis 247 provided an AUC (area under the ROC curve) of 0.88 (95% CI=0.76-0.99, p<0.0001). 248 An optimal cutoff of 632 ng/mL gave 67% sensitivity and 93% specificity. The results 249 provide further evidence that TLP levels are associated with active TB disease. Overall, 250 the results clearly highlight the potential of TLP as a biomarker in the diagnosis of active 251 TB in HIV positive child.

252

#### 253 **DISCUSSION**

254 The wide spectrum of disease observed in children, and the non-specific signs 255 and symptoms especially in young and HIV+ children, contribute to diagnostic delay and 256 missed opportunities to detect TB, which in turn, favors TB disease progression and 257 poor treatment outcomes. There is urgent need to search for a "Rapid Non-sputumbased Biomarker Test for Tuberculosis Detection" (12) .Most of the biomarkers currently 258 studied are host-derived biomarkers including metabolites and cytokines,<sup>(31, 32)</sup> the 259 260 levels of which can be affected by many confounding factors. On the other hand, *Mtb* products can be detected directly in blood, sputum or urine, and are increasingly being 261 used for diagnosis.<sup>(33)</sup> We have characterized a unique biomolecule, *Mtb* modified 262 lipoprotein, which results from a combination of host and *Mtb* pathogen activity. 263 264 Functionally, TLP increases the flux of lipid into activated macrophages, thereby

stimulating their conversion into foamy multi-nucleated macrophages. The TLPstimulated macrophages accumulate lipid bodies but have a distinct phenotype from MDA-LDL-stimulated macrophages (Figure 2). We reason that detection of this biomolecule in patient plasma may withstand the heterogeneity associated with variations derived from host and be pathogen or disease specific. Thus, TLP detection may be used as TB diagnosis in young children.

271 The lipoprotein modification can take place in macrophages in contact with M. 272 tuberculosis. There are also reports demonstrating that extracellular vesicles carrying 273 bacterial components are released from infected macrophages and circulated beyond 274 the site of infection (34), where host lipoproteins could be modified via contact with the 275 extracellular vesicles. In addition, the intracellular bacilli are able to avoid killing by 276 escaping phagosome-lysosome fusion. In certain individuals, especially children below 277 5 years of age and immunosuppressed subjects, the extracellular bacilli may disperse to 278 distant metastatic sites via lymphatics and the bloodstream (35), where host lipoproteins 279 may be modified by direct contact with *M. tuberculosis*. Our data demonstrate that the 280 modified lipoprotein in the present study is distinct from other commonly recognized 281 disease associated LDLs, which are typically negatively charged and smaller in particle 282 size compared to native LDL (36).

The present study established a rapid, non-invasive, and robust sandwich ELISA assay for the detection of a novel biomolecule TLP in plasma. We demonstrate that plasma levels of TLP are significantly distinguishable in HIV positive subjects with active TB disease compared to no TB controls (Figure 2). The significant elevation of plasma levels of TLP in HIV positive subjects with active TB disease suggests the detection of

288 TLP associate with TB active disease in HIV positive subjects. The AUC value of 0.86 289 evidenced the diagnostic value of TLP for TB detection in child. The target product 290 profiles (TPP) adopted by the World Health Organization (WHO) in 2015 for a "Rapid 291 Non-sputum-based Biomarker Test for Tuberculosis Detection" is a diagnostic 292 sensitivity  $\geq$  66% for microbiologically confirmed pediatric TB and 98% specificity for a 293 pediatric test (12). The TPP proposed sensitivity is similar to the sensitivity of the Xpert 294 MTB/RIF assay in microbiologically confirmed samples. Our assay renders 57% 295 sensitivity and 96% specificity, which has the potential to meet the WHO TPP for 296 detection of active TB in children, given the highly heterogenous population of P1041 297 samples, with respect to the bacteriological and clinical status.

298 Samples used in our study were obtained from IMPAACT P1041 clinical trial. The 299 accuracy of TB diagnosis for the P1041 trial samples is not known due to the absence 300 of good pediatric TB diagnostics. In addition, microbiological confirmation of TB disease 301 was not obtained for any of these patients in the P1041 trial. TB disease subjects used 302 in the present study are patients infected with TB presenting clinical symptoms of 303 disease. The ELISA assays were performed retrospectively and the variance in storage 304 conditions might affect the antigen integrity and therefore the accuracy of the assay. We 305 have insufficient samples to include other clinical characteristics of the patients into data 306 analysis. The clinical characteristics include but not limited to BCG administration, 307 immunosuppression status like CD4 counts, or clinical manifestation of tuberculosis 308 (pulmonary and extra-pulmonary TB). The consideration of those characteristics may help define the limitation of our TLP assay or render improved accuracy with the 309 310 combination of other clinical factors.

311 We focused on HIV positive subjects in the current study. TB diagnosis is particularly 312 difficult among HIV co-infected individuals who may have atypical, nonspecific clinical 313 presentation, high rates of smear negative disease and high rates of extrapulmonary TB 314 (37). P1041 samples were obtained from TB endemic settings, therefore patients were 315 typically being diagnosed at more advanced stages than those living in the US. 316 Therefore, the heterogenous stages of TB disease may contribute to the wide dispersity 317 of TLP levels in TB disease subjects (Figure 2A), which is common among TB 318 diagnostic assays. In addition, the duration of anti-tubercular treatment was not 319 consistent among patients in the present study. Change of LDL modification is a 320 dynamic process and may have the potential to monitor treatment outcome. Although 321 not statistically significant, the slight decrease in the TLP level post diagnosis/ anti-322 tubercular treatment of 40 weeks may be related to a reduction in microbial load (Figure 323 S4C). Further studies are required to elucidate the effect of different disease status 324 and/or treatment status on TLP levels in plasma, and to extend our preliminary results 325 to other populations such as HIV negative subjects and adults.

It is a growing notion in the field that a single biomarker will not be sufficient for distinguishing TB status in different patient groups, and multiple biomarkers may be used to increase sensitivity and specificity. Further gains in clinical sensitivity and specificity may be obtained by combining the current assay with other biomarkers or diagnostic tests.

331

# 332 ACKNOWLEDGMENTS

333 Research reported in this publication was supported by the National Heart, Lung, 334 and Blood Institute of the National Institutes of Health under Award Number 335 U01HL127522, and National Institute of Allergy and Infectious Diseases (NIAID) under 336 award number R41AI136071 to Chronus Pharmaceuticals, Inc with a subcontract to 337 Stony Brook University (NSS) and the National Center for Advancing Translational 338 Sciences under award number TL1TR002386 (MFW). Overall support for the 339 International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network 340 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the 341 National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT 342 LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-343 funding from the Eunice Kennedy Shriver National Institute of Child Health and Human 344 Development (NICHD) and the National Institute of Mental Health (NIMH). The content 345 is solely the responsibility of the authors and does not necessarily represent the official 346 views of the NIH.

347

### 348 **REFERENCES**

3491.WHO.2020.Globaltuberculosisreport350<a href="https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf">https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf</a>351<a href="https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf">https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf</a>351<a href="https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf">https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf</a>

Cotton MF, Schaaf HS, Hesseling AC, Madhi SA. 2004. HIV and childhood
tuberculosis: the way forward. Int J Tuberc Lung Dis 8:675-82.

- Marais BJ, Gie RP, Obihara CC, Hesseling AC, Schaaf HS, Beyers N. 2005. Well
   defined symptoms are of value in the diagnosis of childhood pulmonary
   tuberculosis. Arch Dis Child 90:1162-5.
- Moore DP, Klugman KP, Madhi SA. 2010. Role of Streptococcus pneumoniae in
   hospitalization for acute community-acquired pneumonia associated with culture confirmed *Mycobacterium tuberculosis* in children: a pneumococcal conjugate
   vaccine probe study. Pediatr Infect Dis J 29:1099-04.
- 361 5. Zar HJ, Tannenbaum E, Apolles P, Roux P, Hanslo D, Hussey G. 2000. Sputum
   362 induction for the diagnosis of pulmonary tuberculosis in infants and young
   363 children in an urban setting in South Africa. Arch Dis Child 82:305-8.
- Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ. 2008.
   Clinical presentation and outcome of tuberculosis in human immunodeficiency
   virus infected children on anti-retroviral therapy. BMC Pediatr 8:1.
- Jeena PM, Mitha T, Bamber S, Wesley A, Coutsoudis A, Coovadia HM. 1996.
  Effects of the human immunodeficiency virus on tuberculosis in children. Tuber
  Lung Dis 77:437-43.
- Schaaf HS, Gie RP, Beyers N, Smuts N, Donald PR. 1993. Tuberculosis in
  infants less than 3 months of age. Arch Dis Child 69:371-4.
- Jeena PM, Pillay P, Pillay T, Coovadia HM. 2002. Impact of HIV-1 co-infection on
   presentation and hospital-related mortality in children with culture proven
   pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis 6:672-8.

- Madhi SA, Huebner RE, Doedens L, Aduc T, Wesley D, Cooper PA. 2000. HIV-1
  co-infection in children hospitalised with tuberculosis in South Africa. Int J Tuberc
  Lung Dis 4:448-54.
- Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, Enarson
  DA, Donald PR, Beyers N. 2004. The natural history of childhood intra-thoracic
  tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J
  Tuberc Lung Dis 8:392-402.
- Denkinger CM, Kik SV, Cirillo DM, Casenghi M, Shinnick T, Weyer K, Gilpin C,
  Boehme CC, Schito M, Kimerling M, Pai M. 2015. Defining the needs for next
  generation assays for tuberculosis. J Infect Dis 211 Suppl 2:S29-38.
- Abdalla AE, Ejaz H, Mahjoob MO, Alameen AAM, Abosalif KOA, Elamir MYM,
  Mousa MA. 2020. Intelligent Mechanisms of Macrophage Apoptosis Subversion
  by Mycobacterium. Pathogens 9:218.
- 388 14. Genoula M, Marin Franco JL, Dupont M, Kviatcovsky D, Milillo A, Schierloh P,
- 389 Morana EJ, Poggi S, Palmero D, Mata-Espinosa D, Gonzalez-Dominguez E,
- Leon Contreras JC, Barrionuevo P, Rearte B, Cordoba Moreno MO, Fontanals A,
- 391 Crotta Asis A, Gago G, Cougoule C, Neyrolles O, Maridonneau-Parini I,
- 392 Sanchez-Torres C, Hernandez-Pando R, Verollet C, Lugo-Villarino G, Sasiain
- 393 MDC, Balboa L. 2018. Formation of Foamy Macrophages by Tuberculous Pleural
- 394 Effusions Is Triggered by the Interleukin-10/Signal Transducer and Activator of
- 395 Transcription 3 Axis through ACAT Upregulation. Front Immunol 9:459.

- Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. 2009. Foamy macrophages
  and the progression of the human tuberculosis granuloma. Nat Immunol 10:9438.
- Viljoen A, Blaise M, de Chastellier C, Kremer L. 2016. MAB\_3551c encodes the
  primary triacylglycerol synthase involved in lipid accumulation in Mycobacterium
  abscessus. Mol Microbiol 102:611-627.
- 402 17. Caire-Brandli I, Papadopoulos A, Malaga W, Marais D, Canaan S, Thilo L, de
  403 Chastellier C. 2014. Reversible lipid accumulation and associated division arrest
  404 of Mycobacterium avium in lipoprotein-induced foamy macrophages may
  405 resemble key events during latency and reactivation of tuberculosis. Infect
  406 Immun 82:476-90.
- 407 18. Guerrini V, Gennaro ML. 2019. Foam Cells: One Size Doesn't Fit All. Trends
  408 Immunol 40:1163-1179.
- 409 19. Agarwal P, Combes TW, Shojaee-Moradie F, Fielding B, Gordon S, Mizrahi V,
  410 Martinez FO. 2020. Foam Cells Control Mycobacterium tuberculosis Infection.
  411 Front Microbiol 11:1394.
- Watanabe K, Nakazato Y, Saiki R, Igarashi K, Kitada M, Ishii I. 2013. Acroleinconjugated low-density lipoprotein induces macrophage foam cell formation.
  Atherosclerosis 227:51-7.
- 415 21. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. 1998. Oxidized
  416 LDL and malondialdehyde-modified LDL in patients with acute coronary
  417 syndromes and stable coronary artery disease. Circulation 98:1487-1494.

Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wolle
J, Pluckthun A, Virnekas B. 2000. Fully synthetic human combinatorial antibody
libraries (HuCAL) based on modular consensus frameworks and CDRs
randomized with trinucleotides. J Mol Biol 296:57-86.

- Prassler J, Thiel S, Pracht C, Polzer A, Peters S, Bauer M, Norenberg S, Stark Y,
  Kolln J, Popp A, Urlinger S, Enzelberger M. 2011. HuCAL PLATINUM, a
  synthetic Fab library optimized for sequence diversity and superior performance
  in mammalian expression systems. J Mol Biol 413:261-78.
- 426 24. Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, Jean-Philippe P,
  427 McSherry G, Mitchell C, Team PS. 2011. Primary isoniazid prophylaxis against
  428 tuberculosis in HIV-exposed children. N Engl J Med 365:21-31.
- 429 25. Anonymous. A randomized, double blind, placebo controlled trial to determine
  430 the efficacy of isoniazid (INH) in preventing tuberculosis disease and latent
  431 tuberculosis infection among infants with perinatal exposure to HIV.
  432 <u>https://impaactnetwork.org/DocFiles/P1041/P1041V2\_11Jul07.pdf</u>. Accessed 10
  433 Oct 2019.
- Gupta A, Montepiedra G, Gupte A, Zeldow B, Jubulis J, Detrick B, Violari A,
  Madhi S, Bobat R, Cotton M, Mitchell C, Spector S, Impaact N, Team PS. 2016.
  Low Vitamin-D Levels Combined with PKP3-SIGIRR-TMEM16J Host Variants Is
  Associated with Tuberculosis and Death in HIV-Infected and -Exposed Infants.
  PLoS One 11:e0148649.
- 439 27. Yoshida M, Higashi K, Kobayashi E, Saeki N, Wakui K, Kusaka T, Takizawa H,
  440 Kashiwado K, Suzuki N, Fukuda K, Nakamura T, Watanabe S, Tada K, Machi Y,

Mizoi M, Toida T, Kanzaki T, Tomitori H, Kashiwagi K, Igarashi K. 2010. Correlation between images of silent brain infarction, carotid atherosclerosis and white matter hyperintensity, and plasma levels of acrolein, IL-6 and CRP. Atherosclerosis 211:475-9.

Puissegur MP, Lay G, Gilleron M, Botella L, Nigou J, Marrakchi H, Mari B,
Duteyrat JL, Guerardel Y, Kremer L, Barbry P, Puzo G, Altare F. 2007.
Mycobacterial lipomannan induces granuloma macrophage fusion via a TLR2dependent, ADAM9- and beta1 integrin-mediated pathway. J Immunol 178:31619.

450 29. Nezami N, Ghorbanihaghjo A, Rashtchizadeh N, Argani H, Tafrishinejad A,
451 Ghorashi S, Hajhosseini B. 2011. Atherogenic changes of low-density lipoprotein
452 susceptibility to oxidation, and antioxidant enzymes in pulmonary tuberculosis.
453 Atherosclerosis 217:268-73.

30. Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA,
Braunwald E. 1998. Relationship between plasma LDL concentrations during
treatment with pravastatin and recurrent coronary events in the cholesterol and
recurrent events trial. Circulation 97:1446-1452.

458 31. Weiner J, Kaufmann SH. 2014. Recent advances towards tuberculosis control:
459 vaccines and biomarkers. J Intern Med 275:467-80.

460 32. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. 2011. Immunological
461 biomarkers of tuberculosis. Nat Rev Immunol 11:343-54.

- Goletti D, Lee MR, Wang JY, Walter N, Ottenhoff THM. 2018. Update on
  tuberculosis biomarkers: from correlates of risk, to correlates of active disease
  and of cure from disease. Respirology 23:455-466.
- 465 34. Athman JJ, Wang Y, McDonald DJ, Boom WH, Harding CV, Wearsch PA. 2015.
- 466 Bacterial membrane vesicles mediate the release of Mycobacterium tuberculosis
- 467 lipoglycans and lipoproteins from infected macrophages. J Immunol 195:1044-53.
- 468 35. Grosset J. 2003. Mycobacterium tuberculosis in the extracellular compartment:
  469 an underestimated adversary. Antimicrob Agents Chemother 47:833-6.
- 470 36. Orekhov AN. 2018. LDL and foam cell formation as the basis of atherogenesis.
  471 Curr Opin Lipidol 29:279-284.
- 37. Scott L, da Silva P, Boehme CC, Stevens W, Gilpin CM. 2017. Diagnosis of
  opportunistic infections: HIV co-infections tuberculosis. Curr Opin HIV AIDS
  12:129-138.